Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) Other Non Operating Income (2019 - 2025)

BioNexus Gene Lab's Other Non Operating Income history spans 6 years, with the latest figure at $107760.0 for Q3 2025.

  • For Q3 2025, Other Non Operating Income fell 76.85% year-over-year to $107760.0; the TTM value through Sep 2025 reached $1.1 million, down 18.44%, while the annual FY2024 figure was $2.1 million, 326.4% up from the prior year.
  • Other Non Operating Income for Q3 2025 was $107760.0 at BioNexus Gene Lab, down from $209461.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $730105.0 in Q2 2024 and bottomed at -$208468.0 in Q1 2021.
  • The 4-year median for Other Non Operating Income is $99590.0 (2025), against an average of $181532.7.
  • The largest annual shift saw Other Non Operating Income tumbled 122.95% in 2021 before it soared 67.01% in 2022.
  • A 4-year view of Other Non Operating Income shows it stood at $38930.0 in 2021, then tumbled by 276.67% to -$68776.0 in 2022, then skyrocketed by 1081.44% to $674994.0 in 2024, then tumbled by 84.04% to $107760.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Other Non Operating Income are $107760.0 (Q3 2025), $209461.0 (Q2 2025), and $91420.0 (Q1 2025).